Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY. Barraclough A, et al. Among authors: sehn lh. Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251. Blood Adv. 2019. PMID: 31285189 Free PMC article.
Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting.
Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, Searle B, Souliere S, Spinelli JJ, Sutherland J, Connors JM. Sehn LH, et al. Blood. 2007 May 15;109(10):4171-3. doi: 10.1182/blood-2006-11-059469. Epub 2007 Jan 23. Blood. 2007. PMID: 17244675 Free article. Clinical Trial.
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS. Natkunam Y, et al. Among authors: sehn lh. J Clin Oncol. 2008 Jan 20;26(3):447-54. doi: 10.1200/JCO.2007.13.0690. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086797
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Rimsza LM, et al. Among authors: sehn lh. Blood. 2008 Oct 15;112(8):3425-33. doi: 10.1182/blood-2008-02-137372. Epub 2008 Jun 10. Blood. 2008. PMID: 18544678 Free PMC article.
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y. Gratzinger D, et al. Among authors: sehn lh. Br J Haematol. 2010 Jan;148(2):235-44. doi: 10.1111/j.1365-2141.2009.07942.x. Epub 2009 Oct 11. Br J Haematol. 2010. PMID: 19821819 Free PMC article.
Prognostic factors in follicular lymphoma.
Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Relander T, et al. Among authors: sehn lh. J Clin Oncol. 2010 Jun 10;28(17):2902-13. doi: 10.1200/JCO.2009.26.1693. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385990 Review.
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.
Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins CE, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C, Gascoyne RD. Kridel R, et al. Among authors: sehn lh. Blood. 2012 Mar 1;119(9):1963-71. doi: 10.1182/blood-2011-11-391474. Epub 2011 Dec 30. Blood. 2012. PMID: 22210878 Free article.
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma.
Perry AM, Cardesa-Salzmann TM, Meyer PN, Colomo L, Smith LM, Fu K, Greiner TC, Delabie J, Gascoyne RD, Rimsza L, Jaffe ES, Ott G, Rosenwald A, Braziel RM, Tubbs R, Cook JR, Staudt LM, Connors JM, Sehn LH, Vose JM, López-Guillermo A, Campo E, Chan WC, Weisenburger DD. Perry AM, et al. Among authors: sehn lh. Blood. 2012 Sep 13;120(11):2290-6. doi: 10.1182/blood-2012-05-430389. Epub 2012 Jun 26. Blood. 2012. PMID: 22740447 Free PMC article.
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD. Johnson NA, et al. Among authors: sehn lh. J Clin Oncol. 2012 Oct 1;30(28):3452-9. doi: 10.1200/JCO.2011.41.0985. Epub 2012 Jul 30. J Clin Oncol. 2012. PMID: 22851565 Free PMC article.
Treatment and outcomes of primary breast lymphoma.
Caon J, Wai ES, Hart J, Alexander C, Truong PT, Sehn LH, Connors JM. Caon J, et al. Among authors: sehn lh. Clin Breast Cancer. 2012 Dec;12(6):412-9. doi: 10.1016/j.clbc.2012.07.006. Epub 2012 Sep 25. Clin Breast Cancer. 2012. PMID: 23018097
MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS, Atenafu EG, Xuan Y, Waldron L, Reis PP, Sun T, Datti A, Xu W, Kuruvilla J, Good DJ, Lai R, Church AJ, Lam WS, Baetz T, Lebrun DP, Sehn LH, Farinha P, Jurisica I, Bailey DJ, Gascoyne RD, Crump M, Kamel-Reid S. Goswami RS, et al. Among authors: sehn lh. J Clin Oncol. 2013 Aug 10;31(23):2903-11. doi: 10.1200/JCO.2012.45.3050. Epub 2013 Jul 8. J Clin Oncol. 2013. PMID: 23835716
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. Zhou Z, et al. Among authors: sehn lh. Blood. 2014 Feb 6;123(6):837-42. doi: 10.1182/blood-2013-09-524108. Epub 2013 Nov 21. Blood. 2014. PMID: 24264230 Free PMC article.
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, Sehn LH, Fu K, Aoun P, Greiner TC, Chan WC, Bierman PJ, Bociek RG, Armitage JO, Vose JM, Gascoyne RD, Weisenburger DD. Perry AM, et al. Among authors: sehn lh. Br J Haematol. 2014 May;165(3):382-91. doi: 10.1111/bjh.12763. Epub 2014 Feb 8. Br J Haematol. 2014. PMID: 24506200 Free article.
An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.
Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, Johnson N, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C. Chan FC, et al. Blood. 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13. Blood. 2015. PMID: 25395426 Free article.
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW. Sun H, et al. Among authors: sehn lh. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):341-8. doi: 10.1016/j.clml.2014.12.015. Epub 2015 Jan 3. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25656914
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, Brice P, Chavez EA, Kyle AH, Scott DW, Sanders AD, Fabiani B, Slack GW, Minchinton AI, Haioun C, Connors JM, Sehn LH, Steidl C, Gascoyne RD, Salles G. Kridel R, et al. Among authors: sehn lh. Clin Cancer Res. 2015 Aug 1;21(15):3428-35. doi: 10.1158/1078-0432.CCR-14-3253. Epub 2015 Apr 13. Clin Cancer Res. 2015. PMID: 25869385 Clinical Trial.
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD. Scott DW, et al. Among authors: sehn lh. J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3. J Clin Oncol. 2015. PMID: 26240231 Free PMC article.
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O. Pastore A, et al. Among authors: sehn lh. Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6. Lancet Oncol. 2015. PMID: 26256760
Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, de Nully Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M. El-Galaly TC, et al. Among authors: sehn lh. Am J Hematol. 2015 Nov;90(11):1041-6. doi: 10.1002/ajh.24169. Am J Hematol. 2015. PMID: 26260224 Free article.
Cell of origin of transformed follicular lymphoma.
Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM, Scott DW, Gascoyne RD. Kridel R, et al. Among authors: sehn lh. Blood. 2015 Oct 29;126(18):2118-27. doi: 10.1182/blood-2015-06-649905. Epub 2015 Aug 25. Blood. 2015. PMID: 26307535 Free PMC article.
The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.
Alzahrani M, El-Galaly TC, Hutchings M, Hansen JW, Loft A, Johnsen HE, Iyer V, Wilson D, Sehn LH, Savage KJ, Connors JM, Gascoyne RD, Johansen P, Clasen-Linde E, Brown P, Villa D. Alzahrani M, et al. Among authors: sehn lh. Ann Oncol. 2016 Jun;27(6):1095-1099. doi: 10.1093/annonc/mdw137. Epub 2016 Mar 21. Ann Oncol. 2016. PMID: 27002106 Free article.
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.
Hapgood G, Zheng Y, Sehn LH, Villa D, Klasa R, Gerrie AS, Shenkier T, Scott DW, Gascoyne RD, Slack GW, Parsons C, Morris J, Pickles T, Connors JM, Savage KJ. Hapgood G, et al. Among authors: sehn lh. J Clin Oncol. 2016 Jul 20;34(21):2493-500. doi: 10.1200/JCO.2015.65.4194. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269949
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L. Kostakoglu L, et al. Leuk Lymphoma. 2017 Feb;58(2):372-381. doi: 10.1080/10428194.2016.1196815. Epub 2016 Jun 24. Leuk Lymphoma. 2017. PMID: 27339738 Clinical Trial.
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moccia AA, Hitz F, Hoskins P, Klasa R, Power MM, Savage KJ, Shenkier T, Shepherd JD, Slack GW, Song KW, Gascoyne RD, Connors JM, Sehn LH. Moccia AA, et al. Among authors: sehn lh. Leuk Lymphoma. 2017 Feb;58(2):324-332. doi: 10.1080/10428194.2016.1193852. Epub 2016 Jun 27. Leuk Lymphoma. 2017. PMID: 27347845
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ. Schmitz N, et al. Among authors: sehn lh. J Clin Oncol. 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520. Epub 2016 Jul 5. J Clin Oncol. 2016. PMID: 27382100
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O. Jurinovic V, et al. Among authors: sehn lh. Blood. 2016 Aug 25;128(8):1112-20. doi: 10.1182/blood-2016-05-717355. Epub 2016 Jul 14. Blood. 2016. PMID: 27418643 Free PMC article.
Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.
Kansara R, Connors JM, Savage KJ, Gerrie AS, Scott DW, Slack GW, Gascoyne RD, Sehn LH, Villa D. Kansara R, et al. Among authors: sehn lh. Haematologica. 2016 Oct;101(10):e411-e414. doi: 10.3324/haematol.2016.144550. Epub 2016 Jun 16. Haematologica. 2016. PMID: 27479818 Free PMC article. No abstract available.
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.
El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Poulsen MØ, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Bøgsted M, Johnsen HE, Seymour JF, Connors JM, Brown PD, Villa D. El-Galaly TC, et al. Among authors: sehn lh. Br J Haematol. 2016 Dec;175(5):876-883. doi: 10.1111/bjh.14325. Epub 2016 Sep 29. Br J Haematol. 2016. PMID: 27681999 Free article.
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.
Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Kridel R, et al. Among authors: sehn lh. PLoS Med. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec. PLoS Med. 2016. PMID: 27959929 Free PMC article.
Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.
Bashash M, Connors JM, Gascoyne RD, Meissner B, Schuetz JM, Leach S, Slack GW, Berry BR, Hu H, Sehn LH, Brooks-Wilson AR, Spinelli JJ. Bashash M, et al. Among authors: sehn lh. Haematologica. 2017 May;102(5):e199-e202. doi: 10.3324/haematol.2016.159087. Epub 2017 Feb 2. Haematologica. 2017. PMID: 28154089 Free PMC article. No abstract available.
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Johnsen HE, Seymour JF, Connors JM, de Nully Brown P, Bøgsted M, Cheah CY. El-Galaly TC, et al. Among authors: sehn lh. Eur J Cancer. 2017 Apr;75:195-203. doi: 10.1016/j.ejca.2016.12.029. Epub 2017 Feb 23. Eur J Cancer. 2017. PMID: 28237865 Free article.
Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.
Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW. Ennishi D, et al. Among authors: sehn lh. Blood. 2017 May 18;129(20):2760-2770. doi: 10.1182/blood-2016-11-747022. Epub 2017 Mar 28. Blood. 2017. PMID: 28351934 Free article.
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE. Skamene T, et al. Among authors: sehn lh. Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15. Leuk Lymphoma. 2017. PMID: 28504033 Clinical Trial.
Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
Lee LJ, Toze CL, Huang SJT, Gillan TL, Connors JM, Sehn LH, Bruyere H, Leitch H, Ramadan KM, Gerrie AS. Lee LJ, et al. Among authors: sehn lh. Leuk Lymphoma. 2018 Jun;59(6):1356-1363. doi: 10.1080/10428194.2017.1387904. Epub 2017 Oct 16. Leuk Lymphoma. 2018. PMID: 29032719
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R. Mottok A, et al. Among authors: sehn lh. Blood. 2018 Jan 11;131(2):226-235. doi: 10.1182/blood-2017-08-799080. Epub 2017 Nov 9. Blood. 2018. PMID: 29122756 Free PMC article. Clinical Trial.
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM. Pilichowska M, et al. Among authors: sehn lh. Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12. Blood Adv. 2017. PMID: 29296913 Free PMC article.
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. El-Galaly TC, et al. Among authors: sehn lh. Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21. Eur J Cancer. 2018. PMID: 29477102 Free PMC article.
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K, Slack GW, Abou Mourad Y, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Sanford DS, Sutherland HJ, Tucker T, Toze CL, Sehn LH, Broady R, Gerrie AS. Zhu KY, et al. Among authors: sehn lh. Br J Haematol. 2018 Jun;181(6):782-790. doi: 10.1111/bjh.15262. Epub 2018 May 9. Br J Haematol. 2018. PMID: 29741758 Free article.
Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD.
Villa D, Sehn LH, Aquino-Parsons C, Tonseth P, Scott DW, Gerrie AS, Wilson D, Bénard F, Gascoyne RD, Slack GW, Farinha P, Morris J, Pickles T, Connors JM, Savage KJ. Villa D, et al. Among authors: sehn lh. Haematologica. 2018 Dec;103(12):e590-e593. doi: 10.3324/haematol.2018.196782. Epub 2018 Jul 12. Haematologica. 2018. PMID: 30002124 Free PMC article. No abstract available.
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Tsang ES, Villa D, Loscocco F, Visani G, Power M, Guiducci B, Clissa C, Song K, Toze C, Abou Mourad Y, Sutherland H, Sanford D, Nantel SH, Sehn LH, Scott DW, Savage KJ, Connors JM, Gerrie AS, Isidori A. Tsang ES, et al. Among authors: sehn lh. Bone Marrow Transplant. 2019 Mar;54(3):481-484. doi: 10.1038/s41409-018-0328-9. Epub 2018 Aug 31. Bone Marrow Transplant. 2019. PMID: 30171222 No abstract available.
Management of relapsed/refractory DLBCL.
Sarkozy C, Sehn LH. Sarkozy C, et al. Among authors: sehn lh. Best Pract Res Clin Haematol. 2018 Sep;31(3):209-216. doi: 10.1016/j.beha.2018.07.014. Epub 2018 Jul 23. Best Pract Res Clin Haematol. 2018. PMID: 30213390 Review.
High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.
Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW. Chong LC, et al. Among authors: sehn lh. Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572. Blood Adv. 2018. PMID: 30348671 Free PMC article.
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW. Ennishi D, et al. Among authors: sehn lh. J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3. J Clin Oncol. 2019. PMID: 30523716 Free PMC article.
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M. Klanova M, et al. Among authors: sehn lh. Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7. Blood. 2019. PMID: 30617197 Free PMC article. Clinical Trial.
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C. Ennishi D, et al. Among authors: sehn lh. Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31. Cancer Discov. 2019. PMID: 30705065
PD-L1 and tumor-associated macrophages in de novo DLBCL.
McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, Sehn LH, Venstrom JM. McCord R, et al. Among authors: sehn lh. Blood Adv. 2019 Feb 26;3(4):531-540. doi: 10.1182/bloodadvances.2018020602. Blood Adv. 2019. PMID: 30770362 Free PMC article. Clinical Trial.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F. Zelenetz AD, et al. Among authors: sehn lh. Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8. Blood. 2019. PMID: 30850381 Free PMC article. Clinical Trial.
261 results